Oncolytic Viruses Move Forward in Clinical Trials

Clinical trials with oncolytic adenovirus in China.

Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one kind of oncolytic adenovirus with E1B-55KD and partial E3 deleted developed by Shanghai Sunwaybio. Fro...

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses

Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse viruses, often genetically engineered, has advanced to clinical investigation, including phase 3 studies. This diversity of virotherapeutics not only offers interesting opportunities for the implementa...

Clinical inertia: hard to move it forward.

Oncolytic Viruses

1Genelux Corporation, San Diego Science Center, San Diego, CA 92019, USA 2Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, CA 92093, USA 3Department of Biochemistry, University of Wuerzburg, 97074 Wuerzburg, Germany 4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, 97078 Wuerzburg, Germany 5 I...

Clinical trials make a move toward mice

Foretelling the future is often the stuff of science fiction but for a team of scientists at the Novartis Institutes for BioMedical Research (NIBR), it’s their end goal. Led by Juliet Williams, Director of Oncology Pharmacology, and Bill Sellers, Global Head of Oncology, the team has developed a unique system to help predict how cancer drugs might fare well before they enter clinical testing: A...